BARC: A Secreted Marker of Kidney Cancer
- Determine whether bone morphogenetic protein antagonist regulated in cancer (BARC) is
present in urine and serum samples from patients with renal cell carcinoma or
transitional cell carcinoma of the urothelium and from healthy participants and whether
changes in BARC expression levels in these fluids correlate with various disease
- Evaluate BARC's utility as a biomarker of kidney cancer.
- Determine whether differences in BARC levels exist between patients with cancer vs
non-cancer patients visiting the urology clinic.
- Determine whether differences in BARC levels exist among the different types of kidney
- Evaluate serum markers of iron metabolism and determine whether changes in BARC
expression correlates with changes in these systemic iron markers.
- Determine whether the development of an enzyme-linked immunosorbent assay to detect
BARC levels as a diagnostic procedure is feasible and desirable.
OUTLINE: This is a pilot study.
Blood and urine samples are collected. Samples are evaluated by immunoblotting to detect
bone morphogenetic protein antagonist regulated in cancer (BARC) and by mass spectrometry
analysis to detect hepcidin levels. Serum samples are further analyzed for serum iron,
ferritin, and total-iron body capacity. Histology of biopsy samples will be recorded for
patients undergoing nephrectomy for renal cell carcinoma. These patients will undergo a
second collection of blood and urine samples 3 months post-nephrectomy.
Time Perspective: Prospective
Presence of bone morphogenetic protein antagonist regulated in cancer (BARC) in urine and serum samples
Frank M. Torti, MD, MPH
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|